巴瑞替尼治疗成人特应性皮炎8项随机临床试验的汇总安全性分析
该汇总分析纳入8项随机临床试验(6项双盲安慰剂对照、1项双盲长期扩展、1项开放标签长期扩展)中2531例接受巴瑞替尼治疗的中重度特应性皮炎患者,累计暴露2247患者年。结果显示严重感染、机会性感染和结膜疾病发生率低,与安慰剂组相似;常见严重感染为疱疹性湿疹、蜂窝织炎和肺炎。4 mg组单纯疱疹发生率高于2 mg组和安慰剂组。整体安全性与已知特征一致。
要点
- 巴瑞替尼治疗中重度AD的严重感染、机会性感染发生率低,与安慰剂组相似。
- 4 mg组单纯疱疹发生率(6.1%)高于2 mg组(3.6%)和安慰剂组(2.7%)。
- 安慰剂对照期未报告恶性肿瘤、胃肠道穿孔、心血管事件或结核。
核心结论
- 中重度AD患者中巴瑞替尼的汇总安全性分析与已知安全性特征一致。
研究设计与样本
- 汇总8项随机临床试验的患级安全性数据:6项双盲安慰剂对照研究(1项2期、5项3期)、1项双盲随机长期扩展研究和1项开放标签长期扩展研究。
- 共2531例患者接受巴瑞替尼治疗,累计暴露2247患者年,中位治疗持续时间310天。
- 分析数据集包括安慰剂对照集、2-mg–4-mg扩展集和All-bari AD集。
主要发现
- 安慰剂对照期严重感染、机会性感染和结膜疾病发生率低,且治疗组间相似。
- 最常见的严重感染为疱疹性湿疹(n=11,IR=0.5)、蜂窝织炎(n=6,IR=0.3)和肺炎(n=3,IR=0.1);机会性感染4例(IR=0.2)。
- 安慰剂对照期巴瑞替尼治疗患者未报告恶性肿瘤、胃肠道穿孔、经裁定的心血管事件或结核。
- 单纯疱疹发生率:4 mg组6.1%,2 mg组3.6%,安慰剂组2.7%;扩展数据集IR(2 mg=9.6,4 mg=14.5)低于安慰剂对照数据集IR(2 mg=12.4,4 mg=21.3)。
- All-bari AD数据集中,2 mg组有2例经裁定的主要不良心血管事件,4 mg组有2例静脉血栓事件,1例死亡。
临床怎么用
- 临床使用巴瑞替尼治疗中重度AD时,应关注单纯疱疹等感染事件,尤其4 mg剂量组。
- 长期治疗中需监测心血管事件和静脉血栓风险,尽管安慰剂对照期未报告。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in late-stage development for adult patients with moderate-to-severe AD. OBJECTIVE: To report pooled safety data for baricitinib in patients with moderate-to-severe AD in the clinical development program including long-term extension (LTE) studies. METHODS: This analysis included patient-level safety data from six double-blinded, randomized, placebo-controlled studies (one phase 2 and five phase 3), one double-blinded, randomized, LTE study and one open-label LTE study, reported in three data sets: placebo-controlled, 2-mg - 4-mg extended and All-bari AD. Safety outcomes include treatment-emergent adverse events, adverse events of special interest and abnormal laboratory changes. Proportions of patients with events and incidence rates were calculated. RESULTS: Data were collected for 2531 patients who were given baricitinib for 2247 patient-years (median duration 310 days). The frequency of serious infections, opportunistic infections and conjunctival disorders was low and similar between treatment groups in the placebo-controlled period. The most common serious infections were eczema herpeticum [n = 11, incidence rates (IR) = 0.5], cellulitis (n = 6, IR = 0.3) and pneumonia (n = 3, IR = 0.1). There were four opportunistic infections (IR = 0.2). No malignancies, gastrointestinal perforations, positively adjudicated cardiovascular events or tuberculosis were reported in the placebo-controlled period in baricitinib-treated patients. Frequency of herpes simplex was higher in the 4-mg group (6.1%) vs. the 2-mg (3.6%) and placebo group (2.7%); IRs in the extended data set (2-mg IR = 9.6; 4-mg IR = 14.5) were lower vs. the placebo-controlled data set (2-mg IR = 12.4; 4-mg IR = 21.3). In the All-bari AD data set, there were two positively adjudicated major adverse cardiovascular events (2-mg group): two venous thrombosis events (4-mg group) and one death. CONCLUSION: This integrated safety analysis in patients with moderate-to-severe AD confirms the established safety profile of baricitinib.
引用
- Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2020. PMID: 32926462. doi:10.1111/jdv.16948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。